Clinical Pharmacology & Therapeutics · 2013 · 95 citations · 39 references
PharmacyInfectious DiseasesPharmacotherapyPharmacogeneticsPharmacogenomicsVirologyAntiviral TherapyClinical Implementation Of PharmacogeneticsInterferon ResponsesInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentAntiviral Therapy SelectionCombination Antiviral RegimensHepatitis C GenotypesHepatitis C Virus GenotypeHepatitis C Virus ManagementInterferon Alfa TherapyPegylated Interferon AlfaRibavirin-based Regimens
Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.
39
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge, Jacques Fellay, Alexander Thompson et al. · Nature · 2009 · 3.5K citations · Full text
Life Sciences, Genetics, Immunology +13
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Marc G. Ghany, Doris B. Strader, David L. Thomas et al. · Hepatology · 2008 · 3K citations · Full text
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas, Chloe L. Thio, Maureen P. Martin et al. · Nature · 2009 · 2.1K citations
Life Sciences, Genetics, Immunology +11